A detailed history of Squarepoint Ops LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Squarepoint Ops LLC holds 15,000 shares of SNDX stock, worth $237,450. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,000
Holding current value
$237,450
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$11.39 - $21.67 $145,245 - $276,335
12,752 Added 32.46%
52,035 $1.12 Million
Q2 2023

Aug 14, 2023

BUY
$19.35 - $22.31 $760,126 - $876,403
39,283 New
39,283 $822,000
Q3 2021

Nov 15, 2021

SELL
$13.87 - $19.8 $451,815 - $644,985
-32,575 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$13.42 - $25.18 $79,661 - $149,468
5,936 Added 22.28%
32,575 $559,000
Q1 2021

May 17, 2021

SELL
$19.28 - $24.59 $1.24 Million - $1.59 Million
-64,488 Reduced 70.77%
26,639 $596,000
Q4 2020

Feb 16, 2021

BUY
$15.1 - $26.44 $387,209 - $678,000
25,643 Added 39.16%
91,127 $2.03 Million
Q3 2020

Nov 16, 2020

BUY
$13.39 - $17.48 $604,839 - $789,589
45,171 Added 222.37%
65,484 $967,000
Q2 2020

Aug 14, 2020

SELL
$8.94 - $20.98 $107,664 - $252,662
-12,043 Reduced 37.22%
20,313 $301,000
Q1 2020

May 15, 2020

BUY
$6.65 - $12.03 $215,167 - $389,242
32,356 New
32,356 $355,000
Q1 2019

May 15, 2019

SELL
$4.26 - $6.86 $79,240 - $127,602
-18,601 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$3.6 - $8.42 $22,690 - $53,071
6,303 Added 51.25%
18,601 $83,000
Q3 2018

Nov 14, 2018

BUY
$6.33 - $8.08 $77,846 - $99,367
12,298 New
12,298 $99,000
Q1 2018

May 15, 2018

SELL
$8.71 - $14.82 $88,981 - $151,401
-10,216 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$7.8 - $12.94 $79,684 - $132,195
10,216
10,216 $89,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $895M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.